If you are one of the millions of Americans with prediabetes or diabetes and are also overweight, you most likely have some ...

Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease that can lead to permanent damage while producing few noticeable symptoms.

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting approximately 30% of the global population, ...

NASH becomes MASH as medical experts replace stigmatizing "non-alcoholic" liver disease terminology with dignity-focused approach.

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week. The pill, called resmetirom ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more ...

This new therapeutic for advanced-stage liver disease is significant because, until now, ... Of that population, 20% have the more advanced disease form, MASH.

In his 40s, Álvarez was diagnosed with fatty liver disease. Genetics can play a role, and he later learned that his mother had the same condition. "Navigating this journey has deepened my ...

A new study brings researchers closer to better understanding the pathology of the fatty liver disease MASH, which stands for metabolic dysfunction-associated steatohepatitis. MASH is a ...

Madrigal’s stock surges as FDA approves first drug for liver disease MASH ‘Silent’ disease affects an estimated 5% of U.S. adults Last Updated: March 15, 2024 at 8:31 a.m. ET First Published ...